TY  - GEN
AU  - Gordon,Michael S
AU  - Matei,Daniela
AU  - Aghajanian,Carol
AU  - Matulonis,Ursula A
AU  - Brewer,Molly
AU  - Fleming,Gini F
AU  - Hainsworth,John D
AU  - Garcia,Agustin A
AU  - Pegram,Mark D
AU  - Schilder,Russell J
AU  - Cohn,David E
AU  - Roman,Lynda
AU  - Derynck,Mika K
AU  - Ng,Kimmie
AU  - Lyons,Benjamin
AU  - Allison,David E
AU  - Eberhard,David A
AU  - Pham,Thinh Q
AU  - Dere,Randall C
AU  - Karlan,Beth Y
TI  - Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
SN  - 1527-7755
PY  - 2006///0926
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Dimerization
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Enzyme-Linked Immunosorbent Assay
KW  - Female
KW  - Gene Expression Regulation, Neoplastic
KW  - Genes, erbB-2
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Ovarian Neoplasms
KW  - drug therapy
KW  - Predictive Value of Tests
KW  - Receptor, ErbB-2
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2005.05.4221
ER  -